PowerShares DWA Emerging Markets Mom ETF (PIE) At $21.50 Forms Top; Ohr Pharmaceuticals (OHRP) Shorts Up By 29.12%

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) Logo

Ohr Pharmaceuticals Inc (NASDAQ:OHRP) had an increase of 29.12% in short interest. OHRP’s SI was 3.97M shares in March as released by FINRA. Its up 29.12% from 3.08 million shares previously. With 2.80 million avg volume, 1 days are for Ohr Pharmaceuticals Inc (NASDAQ:OHRP)’s short sellers to cover OHRP’s short positions. The SI to Ohr Pharmaceuticals Inc’s float is 7.71%. The stock decreased 2.57% or $0.0058 during the last trading session, reaching $0.2199. About 313,472 shares traded. OHR Pharmaceutical, Inc. (NASDAQ:OHRP) has declined 75.20% since March 30, 2017 and is downtrending. It has underperformed by 86.75% the S&P500.

PowerShares DWA Emerging Markets Mom ETF (PIE) formed multiple top with $23.22 target or 8.00% above today’s $21.50 share price. PowerShares DWA Emerging Markets Mom ETF (PIE) has $279.06 million valuation. The ETF increased 1.75% or $0.37 during the last trading session, reaching $21.5. About 85,204 shares traded. PowerShares DWA Emerging Markets Mom ETF (NASDAQ:PIE) has risen 27.14% since March 30, 2017 and is uptrending. It has outperformed by 15.59% the S&P500.

Investors sentiment increased to 1.45 in Q4 2017. Its up 0.01, from 1.44 in 2017Q3. It improved, as 5 investors sold OHR Pharmaceutical, Inc. shares while 6 reduced holdings. 7 funds opened positions while 9 raised stakes. 5.70 million shares or 24.07% more from 4.60 million shares in 2017Q3 were reported. Susquehanna Intll Gru Llp has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Salzhauer Michael holds 0.01% or 18,715 shares. Stanley invested 0% of its portfolio in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). 139,164 are owned by Northern Corporation. California Employees Retirement Sys accumulated 0% or 78,800 shares. Moreover, Renaissance Techs Ltd Liability has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 1.05M shares. First Manhattan owns 7,215 shares. Moreover, Blackrock has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 418,683 shares. Hightower, a Illinois-based fund reported 27,000 shares. Neuberger Berman Group Inc Ltd Liability reported 46,176 shares. Cannell Peter B & reported 0.03% stake. Leisure Capital Management accumulated 65,463 shares or 0.1% of the stock. Pnc Fin Service Group Incorporated Inc, Pennsylvania-based fund reported 21 shares. Mariner Invest Group Inc Lc holds 0.02% or 30,000 shares in its portfolio. Royal Bank Of Canada stated it has 21 shares or 0% of all its holdings.

Among 3 analysts covering Ohr Pharma (NASDAQ:OHRP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Ohr Pharma has $30 highest and $7 lowest target. $15.67’s average target is 7025.97% above currents $0.2199 stock price. Ohr Pharma had 6 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, August 7, the company rating was maintained by Brean Capital. Roth Capital downgraded OHR Pharmaceutical, Inc. (NASDAQ:OHRP) on Friday, January 5 to “Hold” rating. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 16. The firm has “Hold” rating by Brean Capital given on Wednesday, August 10. H.C. Wainwright initiated it with “Buy” rating and $10 target in Thursday, October 27 report.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $12.42 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.